Ian G Williams
Overview
Explore the profile of Ian G Williams including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haddow L, Sudre C, Sokolska M, Gilson R, Williams I, Golay X, et al.
AIDS Res Hum Retroviruses
. 2019 Jan;
35(5):453-460.
PMID: 30667282
We assessed whether HIV status was associated with white matter hyperintensities (WMH), a neuroimaging correlate of cerebral small vessel disease (CSVD), in men aged ≥50 years. A cross-sectional substudy was...
2.
Haddow L, Godi C, Sokolska M, Cardoso M, Oliver R, Winston A, et al.
Clin Infect Dis
. 2018 Aug;
68(6):1031-1040.
PMID: 30084882
Background: Protease inhibitor monotherapy (PIM) for human immunodeficiency virus (HIV) may exert suboptimal viral control in the central nervous system. We determined whether cerebral blood flow (CBF) and regional brain...
3.
Frater J, Williams I, Hunter C
Aust N Z J Psychiatry
. 2018 Feb;
52(7):715-716.
PMID: 29466866
No abstract available.
4.
Paton N, Goodall R, Dunn D, Franzen S, Collaco-Moraes Y, Gazzard B, et al.
JAMA
. 2012 Jul;
308(4):353-61.
PMID: 22820788
Context: Therapies to decrease immune activation might be of benefit in slowing HIV disease progression. Objective: To determine whether hydroxychloroquine decreases immune activation and slows CD4 cell decline. Design, Setting,...
5.
Hall A, Edwards S, Lapsley M, Connolly J, Chetty K, OFarrell S, et al.
Am J Kidney Dis
. 2009 Sep;
54(6):1034-42.
PMID: 19783343
Background: Randomized control studies have not shown an association between treatment with tenofovir (TDF) and clinically significant kidney toxicity. However, multiple cases of renal tubular toxicity have been described in...
6.
Reid A, Stohr W, Walker A, Williams I, Kityo C, Hughes P, et al.
Clin Infect Dis
. 2008 May;
46(8):1271-81.
PMID: 18444867
Background: We sought to investigate renal function in previously untreated symptomatic human immunodeficiency virus (HIV)-infected adults with CD4(+) cell counts of <200 cells/mm(3) who were undergoing antiretroviral therapy (ART) in...
7.
Asboe D, Williams I, Goodall R, Darbyshire J, Hooker M, Babiker A
Antivir Ther
. 2007 May;
12(1):47-54.
PMID: 17503747
Objective: To evaluate whether the addition of a fourth drug for up to 32 weeks to a standard three-drug antiretroviral combination decreases the risk of virological failure without increasing toxicity...
8.
Newton P, Weller I, Williams I, Miller R, Copas A, Tedder R, et al.
AIDS
. 2006 Mar;
20(2):171-80.
PMID: 16511409
Objectives: The study tests the hypothesis that monocyte derived dendritic cells from HIV-1 infected individuals are normal and can restore impaired CD4 T-cell antigen specific responses. Design: Monocyte derived dendritic...
9.
Gale C, Myers R, Tedder R, Williams I, Kellam P
AIDS Res Hum Retroviruses
. 2004 Jun;
20(5):457-64.
PMID: 15186519
We have developed a high throughput computational tool for assigning subtype to HIV-1, based solely on protease and reverse transcriptase (PR-RT) amino acid sequence, generated routinely for clinical assessment of...
10.
Lindenburg C, Stolte I, Langendam M, Miedema F, Williams I, Colebunders R, et al.
Vaccine
. 2002 May;
20(17-18):2343-7.
PMID: 12009290
Long-term effects of therapeutic vaccination of human immunodeficiency virus (HIV)-1-infected subjects with HIV-1 p17/p24:Ty virus-like particles (p24-VLP) on progression to AIDS, death, a CD4 cell count <or=200 cells/mm(3) and CD4...